Alyeska Investment Group
ABUS icon

Alyeska Investment Group’s Arbutus Biopharma ABUS Stock Holding History

Alyeska Investment Group’s Portfolio ABUS Stock Details ABUS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q2 		– Sell
-21,476
Closed -$375K – 482
2015
Q1 		$375K Buy
+21,476
New +$440K 0.01% 477

Other funds holding ABUS

QF
QVT Financial New York $1.37B AUM 148.1% 1-Year Est. Return
AWG
Alpha Wave Global New York $791M AUM 113.77% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
HM
HealthCor Management New York $109M AUM 10.64% 1-Year Est. Return
BRC
Blue Ridge Capital New York $215M AUM
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
RIM
RS Investment Management San Francisco, California $9.73B AUM 3.24% 1-Year Est. Return
Bank of Montreal
Bank of Montreal Toronto, Ontario, Canada $269B AUM 31.4% 1-Year Est. Return

Alyeska Investment Group's ABUS Position: Q2 2015 in Review

Alyeska Investment Group sold out of Arbutus Biopharma (ABUS) in Q2 2015, closing a stake of 21,476 shares — an estimated $375K sold.

Alyeska Investment Group first reported a position in ABUS in Q1 2015 and held it in 1 quarter. The position peaked at $375K in Q1 2015. 63 funds tracked by Wall St. Rank hold ABUS as of Q2 2015.

  • Alyeska Investment Group reported no remaining Arbutus Biopharma position as of Q2 2015 after selling out during the quarter.
  • Alyeska Investment Group sold 21,476 Arbutus Biopharma shares in Q2 2015, an estimated $375K.
  • Alyeska Investment Group first reported a position in Arbutus Biopharma in Q1 2015 and held it in 1 quarter.
  • Alyeska Investment Group's Arbutus Biopharma position peaked at $375K in Q1 2015.
  • 63 funds tracked by Wall St. Rank held Arbutus Biopharma as of Q2 2015.

Based on Alyeska Investment Group's 13F filing for Q2 2015, filed 14 Aug 2015.